key: cord-0825575-xe3cvf66 authors: Ehaideb, S. N.; Abdullah, M. L.; Abuyassin, B.; Bouchama, A. title: A systematic review uncovers a wide-gap between COVID-19 in humans and animal models date: 2020-07-17 journal: nan DOI: 10.1101/2020.07.15.20147041 sha: 70536943fb086d1e550531ce9df0022a41834a4a doc_id: 825575 cord_uid: xe3cvf66 Background: Animal models of COVID-19 have been rapidly reported after the start of the pandemic. We aimed to assess whether the newly created models reproduce the full spectrum of humans COVID-19. Methods: We searched the Medline, as well as BioRxiv and MedRxiv preprint servers for original research published in English from January 1, to May 20, 2020. We used the search terms COVID-19 OR SARS-CoV-2 AND, animal models, hamsters, nonhuman primates, macaques, rodent, mice, rats, ferrets, rabbits, cats, and dogs. Inclusion criteria were the establishment of animal models of COVID-19 as an endpoint. Other inclusion criteria were assessment of prophylaxis, therapies, or vaccines, using animal models of COVID-19. Findings: 13 peer-reviewed studies and 14 preprints met inclusion criteria. The animals used were nonhuman primates (n=13), mice (n=7), ferrets (n =4), hamsters (n= 4), and cats (n =1). All animals supported high viral replication in the upper and lower respiratory tract associated with mild clinical manifestations, lung pathology and full recovery. Older animals displayed relatively more severe illness than the younger ones. No animal models developed hypoxemic respiratory failure, multiple organ dysfunction, culminating in death. All species elicited a specific IgG antibodies response to the spike proteins, which were protective against a second exposure. Transient systemic inflammation was observed occasionally in Rhesus macaques, hamsters, and mice. Notably, none of the animals unveiled cytokine storm or coagulopathy. Conclusions: Most of the animal models of COVID-19 recapitulated mild pattern of human COVID-19 with full recovery phenotype. No severe illness associated with mortality was observed, suggesting a wide gap between COVID-19 in humans and animal models. Coronavirus disease 2019 (COVID-19) is a febrile respiratory illness due to a novel viral pathogen severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) 1,2 . COVID-19 can progress to acute respiratory distress syndrome (ARDS), multiple organ dysfunction/failure (MOSD), culminating in death [2] [3] [4] . SARS-CoV-2 is a beta coronavirus that binds with a high affinity to angiotensin-converting enzyme (ACE) 2 receptor and uses the transmembrane serine protease (TMPRSS) 2 as coreceptor to gain entry to cells [5] [6] [7] . ACE2 and TMPRSS2 are co-expressed in many tissues and organs, particularly the nasal epithelial cells and alveolar type II cells of the lungs, which may explain in part the easy transmission from person-to-person, and its dissemination within the body in severe and fatal cases [6] [7] [8] [9] [10] [11] [12] [13] . Accordingly, SARS-CoV-2-induced COVID-19 has led to a pandemic that overwhelmed the capacity of most national health systems, resulting in a global health crisis 14 . So far, an estimated 11, 280 million persons in 188 countries were infected, of which 531.000 died 15 . The clinical spectrum of COVID-19 is complex and has been categorized as mild, severe, and critical, representing 81, 14, and 5% 2,3 . The mild pattern comprises patients with either no signs and symptoms or fever and radiological evidence of pneumonia 3 . The severe pattern manifests as rapidly progressive hypoxemic pneumonia involving more than half of the lung with a full recovery phenotype 2, 3 . The critical pattern consists of ARDS requiring respiratory assistance, MOSD that result in death in approximately half of the patients 2,3,16,17 . Mortality was associated with host factors such as old age, comorbidities, and immune response 4 . Viral and immunopathological studies revealed distinct patterns between mild and severe or critical forms of COVID-19 4, [17] [18] [19] [20] [21] [22] [23] [24] [25] . Both severe and critically ill patients displayed higher viral load in the upper respiratory tract than mild cases, together with delayed clearance We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement 35 to identify studies describing the creation of an animal model of COVID-19 as an endpoint (Box1 and supplemental Box1 ). The systematic search identified 101 studies and 326 preprints, of which 400 articles were excluded because they were reviews, non-original articles, or unrelated to the COVID-19 infection ( Fig.1 and supplemental Table 1 ). 13 peer-reviewed studies and 14 preprints were included in the analysis. The studies used Old-world nonhuman primates (n=13) 36-48 , mice (n=7) 49-55 , hamsters (n=4) 55-58 , ferrets (n=4) 59-62 , cats, and dogs (n=1) 62 (Tables 1-4) . Male and female, as well as young and old, were included but with no associated comorbidities. The aims were to investigate the pathogenesis of COVID-19 (n=15), testing drugs and vaccines (n=14), the host immune response (n=6), and the virus dynamic and transmission (n=4) (Tables 1-4). Other animals studied included pigs, ducks, and chickens, however none of them supported SARS-CoV-2 replication, and hence will not be discussed further 62, 63 . All the experimental animals were inoculated with SARS-CoV-2 with various strains, doses, and route of administration that differed across studies (Table 1-4) . Likewise, the time-point for tissue collection and pathological assessment were variables. These together precluded any comparisons between the animal models either intra-species or inter-species. Nonhuman primate models Viral model: Rhesus macaques (n=10) 36-45 , Cynomolgus (n=3) [45] [46] [47] , and African Green model (n=1) 48 from the Old World primates and common marmoset (n=1) 45 from the New World were assessed as models for COVID-19 (Table 1) . SARS-CoV-2 strains, dose and route of inoculation were different across studies. Infection through the intragastric, conjunctival and intratracheal routes elicited no lung pathology, mild and severe interstitial pneumonia, respectively, thus, emphasizing the relevance of the entry site of the virus in the expression of the disease 44 . The animals were euthanized at different time-points post-inoculation ranging from 3 to 33 days. Phenotype: The animals displayed variable clinical manifestations from none to fever, altered respiratory patterns, and other general signs ( Table 1 ). The clinical manifestations were not different between old and young macaques [45] [46] [47] . Structural and ultrastructural examination of the respiratory tract were also variables including mild to moderate interstitial pneumonitis, edema, foci of diffuse alveolar damage with occasional hyaline membrane formation and pneumocytes type II hyperplasia (Table 1) . Old rhesus macaques exhibited more diffuse and severe interstitial pneumonia than young ones 46 . No extrapulmonary injury was documented except in two studies, which revealed inflammatory cells infiltrating the jejunum, and colon, steatosis of the liver, and alteration of myocardial fiber architecture with increased mitochondrial density 32,45 . No mortality was observed in any of the nonhuman primate models. Comparisons between species of nonhuman primates was not possible except in one study, which suggested that rhesus macaques was superior to cynomolgus and common marmoset as models of human COVID-19 45 . Other comparisons suggested that SARS-CoV elicited more severe lung pathology than SARS-CoV-2 and MERS-CoV 47 (Table 1) . The virus replicated rapidly and at higher titers in upper airway and lung and intrathoracic lymph nodes in all four species. The virus was detected in pneumocytes type I and II, and ciliated epithelial cells of nasal, bronchial and bronchiolar mucosa. This differs from MERS-CoV where the virus was mainly present in type II pneumocytes 45 (Table1). Replication of the virus was also demonstrated in jejunum, colon, and rectum 27,36,48 . Viral genome was detected in the blood of rhesus macaques, cynomolgus, and marmoset in one study 45 . Viral replication of nasopharyngeal as well as anal swabs, and lung in old macaques was higher than in young ones 46,47 . SARS-CoV-2 infection-induced IgG antibodies response against the SARS-CoV-2 spike was noted in all species 36,45,47,48 except in marmoset 45 . The antibodies were protective against a second exposure to the virus. There was no difference between males and females; however, young rhesus macaques had lower antibodies titers than the old macaques 45 . The innate immune response to SARS-CoV-2 infection was variable with normal, high or low leucocytes and lymphocytes counts 36,45 . Occasional reduction of CD4 + and CD8 + T cells concentrations was documented 36 as well as transitory release of various cytokines, and chemokines at different days post-inoculation 36,45,48 . Drugs and vaccines: DNA and inactivated virus-based vaccines were evaluated and showed protection in these nonhuman primates. However, the DNA vaccine did not reduce the virus presence in the upper airway, while there was a residual small interstitial pneumonitis in the macaques that received inactivated virus 39,40 . This suggests that none of the vaccines tested so far, displayed a comprehensive protection against SARS-CoV-2 infection. Several candidate DNA vaccines based in various forms of the SARS-CoV-2 Spike (S) protein were also tested in rhesus macaques 38 . The findings revealed that only the vaccine encoding the full-length (S) offered optimal protection against SARS-CoV-2 64 . Nonhuman primates served also for the evaluation of antiviral therapies and medical interventions such as CT-and PET-scanners 46 . Viral model: Wild type mice (BALB/c, C57BL/6); immunodeficient mice (SCID); chimeric mouse expressing human angiotensin-converting enzyme 2 (hACE2), and the RNA-dependent RNA polymerase (SARS1/SARS2-RdRp) were evaluated as models of COVID-19 (Table 2) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.15.20147041 doi: medRxiv preprint Moreover, knockout (KO) mice were generated to test specific immunological pathways or therapy, including ablation of type I (IFNar1-/-) and III interferon (IFN) receptors (IL28r-/-), signal transducer and activator of transcription 2 (STAT2-/-); and serum esterase (Ces1c-/-). Patients' isolates of SARS-CoV-2 from different sources and variable times of passaging on various cell cultures or BALB/c mice were employed ( Table 2 ). The multiple passaging on whole animal adapted the virus to the murine ACE-2 53 . SARS-CoV-2 was also modified through the remodeling of the spike receptor-binding domain (RBD), which enhanced its binding efficiency to murine ACE2 51 . The clinical signs and symptoms varied from none to mild weight loss, arched back, and slight bristles. Whole-body plethysmography was used to measure the respiratory function of the animals and showed a mild to moderate reduction in old more than in young (Table 2) . Likewise, the pathological changes varied according to the experimental models and included peribronchiolar inflammation, lung edema, moderate multifocal interstitial pneumonia, lymphocytes infiltration, and intra-alveolar hemorrhage. Survival of hACE2 mice was decreased at 5 day post-inoculation and was attributed to high viral replication in the brain, while it was minimal in the lung, suggesting a different pathogenic mechanism of death from human COVID-19 51 . Wild type mice showed no pathology as compared to hACE2 mice, indicating that lack of human ACE2 receptor cannot be infected or inefficiently with SARS-CoV-2 49,55 . On the other hand, mouse-adapted SARS-CoV-2 exhibited more severe pathology, particularly in the aged mouse than hACE2 transgenic mouse, suggesting that these models may be more relevant for the study of human COVID-19 51,53 . However, whether the pathogenesis induced by the mouse-adapted SARS-CoV-2 is translatable to human warrants further studies 51,53 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.15.20147041 doi: medRxiv preprint Viral and host interaction: The virus replicated to high titers in the upper and lower respiratory tract in most of the genetically modified mice models but not in wild type. Viral replication was detected outside the respiratory tract in the intestine of hACE2 mice 49 as well as in the liver, and heart in mouse modified SARS-CoV-2 RBD 51 . Increased viral replication in KO mice IFNar1-/-suggested that interferon limited the viral replication 55 . Specific IgG antibodies against SARS-CoV-2 were documented in two studies ( Table 2 ). The IgG antibodies were found to cross-react in their binding to the spike protein of SARS-CoV, however, with no cross-neutralization, hence suggesting the conservation of the same spike protein epitopes among coronaviruses 52 . Proinflammatory cytokines and chemokines were demonstrated in mouse-adapted SARS-CoV-2, and KO mouse ( Table 2 ). The inflammatory response was significantly higher in the old than young mice. Drugs and vaccines: Antiviral therapies, including remdesivir 54 , IFN lambda 51 , and human monoclonal IgG1 antibody against RBD 49 , were tested in these mouse models and produced a protective effect. Likewise, vaccines using viral particles expressing SARS-2-S protein 51 , or an RBD-based vaccine were tested and showed protection 54 . Viral model: Wild type Syrian hamsters and knockout hamsters for signal transducer and activator of transcription 2 (STAT2-/-lacking type I and III interferon signaling) and interleukin 28 receptors (IL28r-/-lacking IFN type III signaling) were reported as models for COVID-19. Patients isolate of SARS-CoV-2 from different sources and different passages on various cell cultures were used (Table 3) . SARS-CoV-2 was administered intranasally at different titers to anesthetized hamsters. Viral transmission between hamsters was demonstrated either through direct contact or indirectly via airborne transmission. Drugs and vaccines: Immunoprophylaxis with early convalescent serum achieved a significant decrease in viral lung load but not in lung pathology 56 . Viral model and phenotype: Ferrets, cats, and dogs were administered intranasally or intratracheally with various doses and strains of SARS-CoV-2 (Table 4 ). Ferrets displayed 1 1 elevated body temperature for several days associated with signs that differed according to the studies. These include decreased activity and appetite, sporadic cough, and no body weight loss [59] [60] [61] [62] . No clinical signs were reported either in cats or in dogs. Histopathological changes: Ferrets exhibited acute bronchiolitis 60,62 , with perivasculitis and vasculitis 62 , but with no discernible pneumonia. Cats disclosed lesions in epithelial nasal, tracheal, and lung mucosa ( Table 2 ). Ferrets, cats, and dogs exhibited specific antibody response against SARS-CoV-2 59,61,62 . A study of the ferret immune response to SARS-CoV-2 revealed a subdued low interferon type I and type III response that contrasts with increased chemokines and proinflammatory cytokine IL6, which is reminiscent of the human response 60 . This systematic review of experimental animal models of SARS-CoV-2 induced-COVID-19 identified 13 peer-reviewed studies and 14 preprints that reported data on nonhuman primates 36-48 , mice 49-55 , hamsters 55-58 , ferrets 59-62 , cats and dogs 62 models of COVID-19. The main findings indicate that most of the animal models could mimic many features of mild human COVID-19 with a full recovery phenotype 3 . They also revealed that older animals display relatively more severe illness than the younger ones 37,45,47,51,53 , which evokes human All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.15.20147041 doi: medRxiv preprint COVID-19 3, 65 . However, none of the animal models replicated the severe or critical patterns associated with mortality as observed in humans with COVID-19 3 . The results of this systematic review are consistent with studies of animal models of SARS-CoV-2 and MERS-CoV, which failed to replicate the full spectrum of humans' illness 66, 67 . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org/10.1101/2020.07.15.20147041 doi: medRxiv preprint 1 4 species 79 . Human and old-world primates have conserved a comparable structure that allows binding with high affinity to the SARS-CoV-2 79 . The new-world primates, hamsters, ferrets, and cats maintained an intermediate affinity, while mice exhibit very low affinity 79 . The latter explains why wild-type mouse does not support SARS-CoV-2 replication, and hence, the necessity to create a chimera that expresses human ACE-2, to enable the use of this species as model of COVID-19 49 . More recently, a study applying single-cell RNA sequencing to nonhuman primate uncovered another explanation that may underlies the difference between old-world primates and humans in expressing the complex phenotype of COVID-19 80 . The study reveals that the cellular expression and distribution of ACE2 and TMPRSS2 which are essential for virus entry in the cells and its spread inside the body differ in the lung, liver, and kidney between the two species. ACE2 expression was found lower in pneumocytes type II and higher in ciliated cells in nonhuman primate lung as compared to humans 39 . This is particularly significant as type II pneumocytes are critical targets of SARS-CoV-2 in humans and the pathogenesis of lung injury/damage. Finally, the innate immune response including the defense system against viruses diverged during evolution both at the transcriptional levels and cellular levels, which may also explain why the SARS-CoV-2 hardly progresses in these animals outside the respiratory system 81 . Taken together, these fundamental differences represent a real challenge to the successful development of an animal model that reproduces human COVID-19. This systematic review has few limitations. First, it is the high number of preprints included in this study that have not been peer-reviewed. Second, the animal models from the same species were difficult to compare across studies, as they used different viral strain, inoculum size, route of administration, and timing of tissue collection. In conclusion, this systematic review revealed that animal models of COVID19 mimic mild human COVID-19, but not the severe form COVID-19 associated with mortality. It also 1 5 disclosed the knowledge generated by these models of COVID-19 including viral dynamic and transmission, pathogenesis, and testing of therapy and vaccines. Likewise, the study underlines the distinct advantages and limitations of each model, which should be considered when designing studies, interpreting pathogenic mechanisms, or extrapolating therapy or vaccines results to humans. Finally, harmonization of animal research protocols to generate results that are consistent, reproducible, and comparable across studies is needed. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. Poor HD, Ventetuolo CE, Tolbert T, et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clinical and Translational Medicine; n/a(n/a). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6(7): e1000097. Munster Finch CL, Crozier I, Lee JH, et al. Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis). bioRxiv 2020: 2020.05.14.096727. Rockx (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . We searched the Medline, as well as BioRxiv and MedRxiv preprint servers for original research describing or using an animal model of SARS-CoV-2 induced COVID published in English from January 1, 2020, to May 20, 2020. We used the search terms "COVID-19" OR "SARS-CoV-2" AND, "animal models", "hamsters", "nonhuman primates", "macaques", "rodent", "mice", "rats", "ferrets", "rabbits", "cats", and " dogs". The preprint servers were included in the search as the field of COVID-19 is developing quickly. Inclusion criteria were establishment of animal models of COVID-19 as endpoint. Other inclusion criteria were assessment of prophylaxis, therapies, or vaccines, using animal models of COVID-19. 101 studies and 326 preprints were screened, of which 13 peer-reviewed studies and 14 preprints were included in the final analysis (Fig.1) . The variables extracted were the population type, study aim, the virus strain used, clinical response, pathology, viral replication, and host response as well as the effects of prophylaxis, drugs, or vaccines. The outcomes were organized according to species and categorized into phenotype (signs or symptoms; histopathology, time-course of the illness and outcome), viral (titer in each tissue organ, detection methods, duration of positivity), and host response (dynamic of seroconversion, inflammatory and hemostatic markers), therapy and vaccine (efficacy, and safety). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . ( 3) Higher replication in old than young More severe in old than young Nose, oropharynx, lung, and BAL (1) Multifocal, mild to moderate, interstitial pneumonia NA NA All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . Rhesus macaques All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. hACE2: chimera expressing human ACE2 receptor. *** C57BL/6 Mice Ces1c-/-: lack a serum esterase, an enzyme that is not present in humans, that reduces markedly the remdesivir half-life. † † † WPH: whole-body plethysmography All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A pneumonia outbreak associated with a new coronavirus of probable bat origin A Novel Coronavirus from Patients with Pneumonia in China Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Viral and host factors related to the clinical outcome of COVID-19 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany SARS-CoV-2 is transmitted via contact and via the air between ferrets Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2 Susceptibility of tree shrew to SARS-CoV-2 infection Autopsy in suspected COVID-19 cases Baseline Characteristics and Outcomes of Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy Is there an ideal animal model for SARS? Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Management of COVID-19 Respiratory Distress Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine Lung pathology of fatal severe acute respiratory syndrome Endothelial cell infection and endotheliitis in COVID-19 Analysis of complement deposition and viral RNA in placentas of COVID-19 patients The stimulation of thrombosis by hypoxia Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 A major outbreak of severe acute respiratory syndrome in Hong Kong All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 5 intraperitoneal. ‡ Viral replication: RNA copies (PCR), viral antigen (Immunostaining), viral particles (electron microscopy). § dpi: day post-inoculation.